Phoenix Nest

What Phoenix Nest does

Phoenix Nest Inc. is a Brooklyn-based, privately held clinical-stage biotech founded around 2014 by an alliance of parents whose children are affected by Sanfilippo syndrome, an ultra-rare lysosomal storage disorder causing progressive pediatric neurodegeneration. The company develops three therapeutic candidates: JLK-247, a self-complementary AAV9 vector gene therapy delivering a functional HGSNAT gene via intrathecal administration for Sanfilippo Type C (FDA Orphan Drug Designation granted); ALL-027, an intracerebroventricular recombinant GNS enzyme replacement therapy for Sanfilippo Type D; and AVP-6, a synthetic peptide for intranasal nose-to-brain delivery designed to address synaptic dysfunction across all four Sanfilippo subtypes (A–D). Provisional patents have been filed for JLK-247 and AVP-6.

The company also operates three observational natural history studies (JLK-447, JLK-448, ALL-127) that use its proprietary HIPAA/GDPR-compliant C-RARE video recording application to capture longitudinal real-world evidence from ultra-rare patient families, with the stated objective of identifying functional endpoints for future interventional trials. Revenue is currently generated exclusively through non-dilutive grant funding rather than product sales, with cumulative capital of roughly $18.96M raised from NIH/NINDS SBIR/STTR awards, Cure Sanfilippo Foundation, Vaincre les Maladies Lysosomales, and Sanfilippo Sud. Phoenix Nest's go-to-market is a hybrid of enterprise-style pharma partnering and community-led patient advocacy engagement, and the company actively seeks licensing or co-development partners to advance candidates through clinical development and commercialization.

Name

Phoenix Nest

Legal name

Phoenix Nest Inc.

Website

https://phoenixnestbiotech.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Phoenix Nest is a Brooklyn-based clinical-stage biotech developing gene therapy, enzyme replacement, and peptide treatments for ultra-rare Sanfilippo syndrome types A–D, funded primarily through NIH SBIR/STTR grants and patient foundation grants and serving the affected pediatric patient population.

Ownership category

akta.pro rank

Product category

Rare Disease Therapeutics / Lysosomal Storage Disorder Biotech

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

akta.pro secondary industries

Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN), Enzyme Replacement & Metabolic Disorder Therapies (HLAIAIAB)

Keywords

• Rare disease therapeutics
• Gene therapy development
• Enzyme replacement therapy
• Natural history studies
• Lysosomal storage disorders

Headquarters

HQ city

Brooklyn

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. NIH/NINDS Grant Funding: Phoenix Nest receives Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants from NIH/NINDS to fund research programs, including vector manufacturing, GLP toxicology studies, and clinical outcome assessments.
2. Foundation Funding: Funding from patient advocacy organizations including Cure Sanfilippo Foundation and Sanfilippo Sud to support specific research programs for gene therapy and natural history studies.
3. Strategic Partnerships and Licensing: Phoenix Nest seeks to license technologies to larger pharmaceutical partners and enter strategic co-development arrangements to advance treatments through clinical development and eventual commercialization.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Phoenix Nest develops experimental therapeutics for Sanfilippo syndrome (Mucopolysaccharidosis III), an ultra-rare lysosomal storage disease. The pipeline comprises three drug candidates: JLK-247, an AAV9-based gene therapy for MPS IIIC; ALL-027, an enzyme replacement therapy for MPS IIID; and AVP-6, a synthetic peptide for intranasal delivery across all Sanfilippo subtypes. The company also runs three natural history studies (JLK-447, JLK-448, ALL-127) using its proprietary C-RARE video recording application to collect real-world evidence.

Product overview

Phoenix Nest is a niche biotech company developing treatments for Sanfilippo syndrome, an ultra-rare lysosomal storage disease. The company's therapeutic pipeline includes three drug candidates: JLK-247 (gene therapy using AAV9 vector for MPS IIIC, FDA Orphan designated), ALL-027 (enzyme replacement therapy for MPS IIID), and AVP-6 (synthetic peptide for intranasal delivery across multiple subtypes). Complementing the drug development programs, Phoenix Nest conducts three natural history studies (JLK-447, JLK-448, ALL-127) to characterize disease progression, utilizing a proprietary video recording application called C-RARE for real-world evidence collection. The company has received multiple NIH/NINDS SBIR grants and Cure Sanfilippo Foundation funding to support its programs.

Differentiator

Problem solved

Functional benefit

Brands

• C-RARE: Clinical recording application for Real-world Evidence, used in Phoenix Nest's observational studies (ALL-127, JLK-447, JLK-448). Features three questionnaires and 12 daily living and social engagement activities to be performed by patients and videotaped by caregivers. Designed to capture disease symptoms and progression and help identify functional endpoints for interventional trials.
• Cure Sanfilippo Foundation

Products and services

• JLK-247

Quantifiable outcome

• JLK-247 received FDA Orphan Drug Designation for Sanfilippo syndrome Type C
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• University of Texas SouthwesterncoreStrategic or Co-development PartnerAcademic collaborator conducting dose-response studies for JLK-247 gene therapy under Dr. Stephan Gray. UT Southwestern serves as a key research partner for preclinical proof-of-concept studies. Site for JLK-448 study coordination.
• ConnectMPSminorStrategic or Co-development PartnerGlobal patient registry collaboration connecting MPS and mucolipidosis patient organizations. Phoenix Nest directs families to ConnectMPS registry for patient data collection and research advancement. Registry supports patient recruitment for natural history studies.
• Cure Sanfilippo FoundationcoreStrategic or Co-development PartnerUmbrella foundation combining patient advocacy organizations including Jonah's Just Begun. Supports Phoenix Nest through funding, patient advocacy, and helping families access information about Sanfilippo syndrome treatments and clinical trials.
• National MPS SocietyminorStrategic or Co-development PartnerNon-profit organization dedicated to supporting families affected by mucopolysaccharidoses. Partnered in ConnectMPS registry development and supports patient community outreach and education.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Abeona Therapeutics: Abeona Therapeutics is a clinical-stage gene therapy company developing AAV-based therapies for Sanfilippo syndrome (MPS IIIA and IIIB), the most directly comparable peer to Phoenix Nest's MPS IIIC and IIID gene therapy programs. Both companies are tackling Sanfilippo subtypes with AAV-mediated CNS delivery, making Abeona the closest head-to-head competitor.
• Lysogene: Lysogene is a clinical-stage gene therapy company developing LYS-SAF302, an AAVrh10-based gene therapy for MPS IIIA. As a Sanfilippo-focused AAV gene therapy peer, Lysogene shares Phoenix Nest's modality (intracerebral AAV delivery), target indication family (MPS III), and clinical translation challenges in ultra-rare pediatric CNS disease.

Broad incumbents

• BioMarin Pharmaceutical: BioMarin is an established rare disease biotech with a portfolio of enzyme replacement therapies for MPS disorders (Aldurazyme, Naglazyme, Vimizim). While not focused on Sanfilippo subtypes, BioMarin validates the MPS ERT commercial model that ALL-027 aspires to replicate and represents a potential strategic acquirer or licensing partner.
• Ultragenyx Pharmaceutical: Ultragenyx is a commercial-stage rare disease biotech with programs spanning MPS and other lysosomal storage disorders, including gene therapy approaches. It is comparable to Phoenix Nest as a broader rare-disease platform with overlapping disease biology and similar development/commercialization pathways for ultra-rare enzyme and gene therapies.

Emerging players

• REGENXBIO: REGENXBIO develops the AAV9 and AAVrh10 platforms used by many MPS gene therapy programs, including potential applications in Sanfilippo syndrome. As the underlying AAV technology licensor, REGENXBIO is comparable to Phoenix Nest as a key infrastructure enabler for the JLK-247 gene therapy approach and a potential IP/licensing counterparty.
• Passage Bio: Passage Bio is a clinical-stage gene therapy company developing AAV-delivered therapies for rare CNS disorders, including pediatric neurodegenerative conditions. It is comparable to Phoenix Nest as a peer AAV-CNS gene therapy developer navigating similar regulatory, manufacturing, and clinical endpoint challenges in ultra-rare neuropediatric indications.
• Taysha Gene Therapies: Taysha Gene Therapies is a clinical-stage AAV gene therapy company with a pipeline centered on rare CNS diseases, including pediatric neurodegenerative programs. It is comparable to Phoenix Nest as a peer in modality (AAV CNS delivery), patient population (rare pediatric), and strategic positioning around ultra-rare disease partnerships.
• Denali Therapeutics: Denali Therapeutics develops engineered enzyme replacement and CNS-penetrant therapeutics for lysosomal storage disorders and neurodegeneration. Comparable to Phoenix Nest through overlapping lysosomal biology, BBB-penetrant ERT delivery (relevant to ALL-027), and focus on rare neurodegenerative diseases.

Others

• Cure Sanfilippo Foundation: Cure Sanfilippo Foundation is the leading patient advocacy organization funding Sanfilippo syndrome research and has provided multiple grants to Phoenix Nest. While not a commercial competitor, it is a key ecosystem participant shaping funding, patient recruitment, and policy for the Sanfilippo research community in which Phoenix Nest operates.
• National MPS Society: National MPS Society is a patient advocacy organization supporting families affected by mucopolysaccharidoses, including Sanfilippo syndrome, and is a ConnectMPS registry partner with Phoenix Nest. It is comparable as an ecosystem enabler influencing patient recruitment, awareness, and policy across the same disease family.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/PhoenixNestInc
• LinkedInlinkedin.com/company/phoenix-nest-inc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phoenix Nest